Both technically right, but just to prevent confusion, the position given by jnmaciuch and in the anxiety paper, is using GRCh37 assembly coordinates, while the one I gave is in GRCh38 coordinates, which is the assembly used by the DecodeME summary stats and LocusZoom above.
(Though it's close...
Symptom Clusters in ME/CFS Reflect Distinct Neuroimmune and Autonomic Pathophysiological Mechanisms: A Translational Model
Habermann-Horstmeier, Lotte; Horstmeier, Lukas Maximilian
[Line breaks added]
Background
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating...
The gene expression predictions were the only ones I tested so far (because that's the only ones I really understand what they are), but there are several other prediction types that might be useful.
Maybe while the top variant in DecodeME predicts changes in expression in lots of genes, there...
Posts moved from: Genetics: Chromosome 20: ARFGEF2, CSE1L, STAU1
There's a lot more for me to read about it to understand, but it's basically a machine learning model trained with lots of genetic and other data to look at a string of DNA (up to 1 million base pairs) and predict various things...
Hmm, yeah, the caption says each point is an image, but the number of points seem to add up to the number of individuals, so maybe they labeled it wrong?
I think >= 10 images of cells per person, if I'm understanding this right:
I don't have the energy right now to read this and try to figure out what exactly they mean by images/replicates etc. But I'd agree that if the right panel of 1B is based on a Mann-Whitney of many points per individual...
In this post? https://www.s4me.info/threads/plasma-cell-targeting-with-the-anti-cd38-antibody-daratumumab-in-me-cfs-a-clinical-pilot-study-2025-fluge-et-al.44736/post-672520
That table is showing baseline steps. I see Table 2 in the study has step count at 17–21 mo, but on a skim, I don't see a...
Is it 6? Looking at the 6 "responders" in Supplementary Table 1, these are the changes in step count over a year:
And the non-responders:
Also, are the criteria for being classified as a responder and the time period for step count measurement the same when you talk about 1000 step count...
Ok, but this doesn't change the issue outlined in the scenario above.
If a study puts the people who have a small increase in step count due to a (very minor) benefit from Rituximab, along with naturally recovered individuals, into a responder group, while it doesn't put anyone taking Dara...
Ah, sorry. I didn't realize you were comparing to responders in the Rituximab study.
I think there might be some statistical issues with comparing averages of responders only. One way to think of it is, imagine both studies have a small number of individuals with a huge step count increase of...
If we're talking about averages, it has to be about the whole group. Otherwise, it would be cherrypicking - the same as if we found one person in the Rituximab study with a 5000 step count increase, called them a responder, and were comparing to that.
From Dara trial:
So average increase of...
It was a claim by Lawrence Afrin in one of his books. See this post: https://www.s4me.info/threads/mast-cell-activation-syndrome-mcas-discussion-thread.16483/post-666242
If you're wondering about the AlphaGenome scores for this variant, it's pretty much the same as other indels in the area, in terms of high scores (though with some sign flips).
Edit: This is from the excel file in this post...
I think Nath is following a T cell exhaustion-type idea, where there is some sort of antigen that the immune system can't clear. It seems that inhibiting PD-1 increases immune response.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.